Galmed Pharmaceuticals Ltd. (GLMD)
Market Cap | 11.84M |
Revenue (ttm) | n/a |
Net Income (ttm) | -22.68M |
Shares Out | 25.20M |
EPS (ttm) | -0.90 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 15,456 |
Open | 0.460 |
Previous Close | 0.450 |
Day's Range | 0.420 - 0.470 |
52-Week Range | 0.290 - 1.838 |
Beta | 1.12 |
Analysts | Sell |
Price Target | 1.02 (+117.07%) |
Earnings Date | May 1, 2023 |
About GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it eng... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for GLMD stock is "Sell." The 12-month stock price forecast is $1.02, which is an increase of 117.07% from the latest price.
News

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammato...

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
Expands foundational patent protection for Galmed's innovative first-in- class drug Aramchol through the end of 2034 This patent provides protection for Aramchol per se, not limited to any therapeutic...

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
TEL AVIV, Israel , Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5M...

Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade
Galmed Pharmaceuticals (GLMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
TEL AVIV, Israel , Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramcho...

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model
Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (IBD) Data reinforcing the expansion of Aramchol's Clinical Development to...

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel , June 17, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and i...

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results
TEL AVIV, Israel , May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and infl...

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects
Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis The Open-Label Part of the A...

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results
- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m.

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment
- Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis. ...

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2
TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramch...

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt
TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammat...

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly redu...

Galmed announces positive results of Phase 1 study of Amilo-5MER
TEL AVIV, Israel, Jan. 10, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory...

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results
TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement
-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations -- -- Statisti...

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study
TEL AVIV, Israel, Nov. 1, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory ...

Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine
TEL AVIV, Israel, October 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammat...

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific seq...

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound
TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory...

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study
TEL AVIV, Israel, Aug. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory...

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
TEL AVIV, Israel, Aug. 5, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial
The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR study without the need for additional studies ot...

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory ...